D'Alvise Janelle 4
4 · Acasti Pharma Inc. · Filed Nov 16, 2021
Insider Transaction Report
Form 4
D'Alvise Janelle
DirectorPRESIDENT & CEO
Transactions
- Award
Stock Options (Right to Buy)
2021-11-12+655,500→ 655,500 totalExercise: $1.63Exp: 2031-11-12→ Class A Common Shares (655,500 underlying)
Footnotes (2)
- [F1]Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant.
- [F2]Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months.